The US Medicare Payment Advisory Commission’s first public presentation on analyses based on Part D rebate data show that drug price inflation in the program is, in fact, relatively high – even after accounting for rebates.
In a presentation during MedPAC’s 7-8 April meeting, MedPAC staff showed a comparison of the gross Part D drug spending...








